Biotech Values

[DewDiligence]

>In post 29209, you go out of your way to slight a company which "competes" with one of your own "picks." (IDIX)<

Again, you show a misunderstanding of my post. The gaffe by ANDS’ CFO on the BofA webcast--calling HBV an RNA virus--was notable, but that doesn’t make me like ANDS less. I mentioned the gaffe because it shows the dangers of having a financial executive be the front person in an investor presentation that covers a science-rich subject such as hepatitis.

>We all know that you have a nasty habit of doing so.<

Yes, indeed everyone knows that. You are so perceptive, Thomas.